KPRX

Stats

Summary

traded on nasdaq capital market, stock symbol eyeg, eyegate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“cmha-s”), a modified form of the natural polymer hyaluronic acid (“ha”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. our first cmha-s-based product candidate, the eyegate ocular bandage gel (“obg”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“prk”) surgery. our initial product candidate from our second platform is egp-437, incorporates a reformulated topically active corticosteroid, dexamethasone

Market Cap: 18.4 Million

Primary Exchange: NASDAQ

Website: http://www.eyegatepharma.com/

Shares Outstanding: 26.3 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.6339551859088439

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 415 trading days

From: 2022-10-06 To: 2024-03-07

Lowest Point: